On January 28, 2025, the Company received clearance of its IND from the FDA to initiate a first-in-human Phase 1 dose escalation clinical trial to evaluate one of its lead drug candidates, HCW9302, in ...

In an effort to understand how brain cells exchange chemical messages, scientists say they have successfully used a highly ...

Houston - March 28, 2025 (Investorideas.com Newswire) KULR Technology Group, Inc. ( NYSE American: KULR) (the "Company" or ...

Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it ...

Social media ripped the New York Yankees' national anthem singer in their season opener against the Milwaukee Brewers.

Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity ...

General and administrative expense for the year ended December 31, 2024 increased to $4.7 million, compared to $4.2 million for the year ended December 31, 2023 primarily due to increased salaries and ...

A genetic change that boosts a cell's aerobic capacity while also protecting it from excess stress could explain how horses became such powerful athletes, according to a new study in Science.

Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...

However, these plasma cells don’t form an actual tumor or mass, and they don’t cause the other health problems that can be seen in multiple myeloma. MGUS doesn’t damage bones or cause high calcium ...

Cell adhesion is the process by which cells form contacts with each other or with their substratum through specialized protein complexes. Intercellular adhesion can be mediated by adherens ...

Stage 4 non-small cell lung cancer (NSCLC) is the most advanced form of the condition and can be challenging to treat. Treatments include chemotherapy, surgery, immunotherapy, and radiotherapy.